Doğan KÖSE, Melike EMİROĞLU, Yavuz KÖKSAL

High-risk febrile neutropenia and its management in childrenwith solid tumors and lymphoma

Background/aim: The clinical characteristics and treatment results of febrile neutropenia attacks that occurred in patients with lymphoma and solid tumors were analyzed. Materials and methods: A total of 50 patients with 94 high-risk attacks were evaluated for malignant diseases in this study. Results: The fever etiology was determined as clinical (50%), microbiological (5.31%), clinical-microbiological (5.31%), or unknown (39.3%). A few of the attacks (21.3%) were observed in lymphoma cases and 77.7% were observed in patients with solid tumors. Patients who were in remission had 59.6% of the attacks, and 39.4% occurred in patients not in remission. Among the groups tested, 73% (the imipenem/amikacin group) and 47.9% (the piperacillin-tazobactam/amikacin group) of patients were in remission. Glycopeptide addition rates in these groups were 22.2% and 40.8% and antifungal addition rates were 8.8% and 18.3%, respectively. Conclusion: Clinical progress was more problematic in patients who were not in remission during the attacks. This was due to the fact that some patients had other factors that placed them in the high-risk group, as well as increased C reactive protein and procalcitonin values on the first day. Therefore, it may not be accurate to associate the success achieved in the different treatment regimens with antibiotics alone.

Anahtar Kelimeler:

Childhood, febrile, high risk, neutropenia

High-risk febrile neutropenia and its management in childrenwith solid tumors and lymphoma

Keywords:

Childhood, febrile, high risk, neutropenia,

PDF

___

Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52: e56–93.
Sigurdardottir K, Digranes A, Harthug S, Nesthus I, Tangen JM, Dybdahl B, Meyer P, Hopen G, Lİkeland T, Grİttum K et al. A multi-centre prospective study of febrile neutropenia in Norway: microbiological findings and antimicrobial susceptibility. Scand J Infect Dis 2005; 37: 455–464.
Pizzo PA. Empirical therapy and prevention of infection in the immunocompromised host. In: Mandell GL, Bennett JE, editors. Principles and Practice of Infectious Diseases. 5th ed. Philadelphia, PA, USA: Churchill Livingstone; 2000. pp. 3102– 3110.
Savoie ML, Nevil TJ, Song KW, Forrest DL, Hogge DE, Nantel SH, Shepherd JD, Smith CA, Sutherland HJ, Toze CL et al. Shifting to outpatient management of acute myeloid leukemia: a prospective experience. Ann Oncol 2006; 17: 763–768.
Viden HH, Grundy PE, Robinson JL. Early discontinuation of intravenous antimicrobial therapy in pediatric oncology patients with febrile neutropenia. BMC Pediatr 2005; 5: 1–6.
Castagnola E, Fontana V, Caviglia I, Caruso S, Faraci M, Fioredda F, Garrè ML, Moroni C, Conte M, Losurdo G et al. A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin Infect Dis 2007; 45: 1296–1304.
Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a retrospective, two center validation of a prediction rule. J Clin Oncol 1991; 10: 316–322.
Walsh TJ, Roilides E, Groll AH, Gonzalez C, Pizzo PA. Infectious complications in pediatric cancer patients. In: Pizzo PA, Poplac DG, editors. Principles and Practice of Pediatric Oncology. 5th ed. Philadelphia, PA, USA: Lippincott Williams & Wilkins; 2006. pp. 1269–1329.
Ramphal R, Grant RM, Dzolganovski B, Constantin J, Tellier R, Allen U, Weitzman S, Matlow A, Petric M, Sung L. Herpes simplex virus in febrile neutropenic children undergoing chemotherapy for cancer: a prospective cohort study. Pediatr Infect Dis 2007; 26: 700–704.
Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med 1985; 145: 1621–1629.
Greenberg D, Moser A, Yagupsky P, Peled N, Hofman Y, Kapelushnik J, Leibovitz E. Microbiological spectrum and susceptibility patterns of pathogens causing bacteremia in pediatric febrile neutropenic oncology patients: comparison between two consecutive time periods with use of different antibiotic treatment protocols. Int J Antimicrob Agents 2005; 25: 469–473.
Vural S, Erdem E, Gulec SG, Yildirmak Y, Kebudi R. Imipenem- cilastatin versus piperacillin-tazobactam as monotherapy in febrile neutropenia. Pediatr Int 2010; 52: 262–267.
Hakim H, Flynn PM, Knapp KM, Srivastava DK, Gaur AH. Etiology and clinical course of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol 2009; 31: 623–629.
Jaye DL, Waites KB. Clinical applications of C-reactive protein in pediatrics. Pediatr Infect Dis J 1997; 16: 735–746.
Karzai W, Oberhoffer M, Meier-Hellmann A, Reinhart K. Procalcitonin - a new indicator of the systemic response to severe infections. Infection 1997; 25: 329–334.
Südhoff T, Giagounidis A, Karthaus M. Evaluation of neutropenic fever: value of serum and plasma parameters in clinical practice. Chemotherapy 2000; 46: 77–85.
Maschmeyer G. Interventional antimicrobial therapy in febrile neutropenic patients. Diagn Microbial Infect Dis 1999; 34: 205–212.
Çağatay AA, Punar M, Nalçaçı M, Özsüt H, Eraksoy H, Atamer T, Dinçol G, Çalangu S. Hematolojik malignitesi olan hastalarda febril nötropeni etkenleri. Klimik Dergisi 2001; 14: 7–9 (in Turkish).
Rolston KV. Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia. Clin Infect Dis 2005; 40 (Suppl. 4): S246–252.
Pizzo PA. Management of fever in patients with cancer and treatment induced neutropenia. N Engl J Med 1993; 328: 1323–1332.
Hamidah A, Rizal AM, Nordiah AJ, Jamal R. Piperacillin– tazobactam plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients. Singapore Med J 2008; 49: 26–30.
Norrby SR. Carbapenems. Med Clin North Am 1995; 79: 745– 759.
Sipsas NV, Bodey GP, Kontoyiannis DP. Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer 2005; 103: 1103–1113.
Oztoprak N, Piskin N, Aydemir H, Celebi G, Akduman D, Keskin AS, Gokmen A, Engin H, Ankarali H. Piperacillin– tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital. Jpn J Clin Oncol 2010; 40: 761–767.
Düzova A, Kutluk T, Kanra G, Büyükpamukçu M, Akyüz C, Seçmeer G, Ceyhan M. Monotherapy with meropenem versus combination therapy with piperacillin plus amikacin as empiric therapy for neutropenic fever in children with lymphoma and solid tumors. Turk J Pediatr 2001; 43: 105–109.
Paul M, Yahav D, Bivas A, Fraser A, Leibovici L. Anti- pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams. Cochrane Database Syst Rev 2010; 10: 5197.
Sanz MA, Bermşdez A, Rovira M, Besalduch J, Pascual MJ, Nocea G, Sanz-Rodríguez C. Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study. Curr Med Res Opin 2005; 21: 645–655.
Kebudi R. Nötropenik ateş. In: Özkan A, editor. Pediatrik Onkoloji. 3rd ed. İstanbul, Turkey: Nobel; 2009. pp. 1251–1262 (in Turkish).
Hann I, Viscoli C, Paesmans M, Gaya H, Glauser M. A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Br J Haematol 1997; 99: 580–588.